Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19.
作者信息
Abraham Jonathan
机构信息
From Harvard Medical School and Brigham and Women's Hospital, Boston.
出版信息
N Engl J Med. 2022 Jun 9;386(23):2236-2238. doi: 10.1056/NEJMe2205563.
Abstract
摘要
相似文献
1
Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19.半衰期延长的单克隆抗体预防新型冠状病毒肺炎
N Engl J Med. 2022 Jun 9;386(23):2236-2238. doi: 10.1056/NEJMe2205563.
2
Engineering monoclonal antibodies for COVID-19 prophylaxis.用于 COVID-19 预防的工程单克隆抗体。
Med. 2022 Mar 11;3(3):157-158. doi: 10.1016/j.medj.2022.02.004.
3
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.肿瘤治疗性单克隆抗体的药代动力学/药效学关系：第 1 部分，单克隆抗体、抗体药物偶联物和双特异性 T 细胞衔接器。
Eur J Cancer. 2020 Mar;128:107-118. doi: 10.1016/j.ejca.2020.01.005. Epub 2020 Feb 6.
4
PDL-1/PD1 inhibitors: antibody or antinobody?程序性死亡受体配体1/程序性死亡蛋白1抑制剂：抗体还是抗抗体？
Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23.
5
Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?-Potential therapeutic applications.达雷妥尤单抗能否诱导浆母细胞淋巴瘤中浆母细胞的成熟？-潜在的治疗应用。
Eur J Haematol. 2021 Apr;106(4):589-592. doi: 10.1111/ejh.13584. Epub 2021 Feb 2.
6
Antibody engineers seek optimal drug targeting TIGIT checkpoint.抗体工程师寻求靶向TIGIT检查点的最佳药物。
Nat Biotechnol. 2020 Sep;38(9):1007-1009. doi: 10.1038/s41587-020-0666-1.
7
[SARS-CoV-2 neutralizing monoclonal antibodies: a potential breakthrough in the early treatment of Covid-19 in high-risk patients].[严重急性呼吸综合征冠状病毒2中和单克隆抗体：高危患者新冠肺炎早期治疗的潜在突破]
Ned Tijdschr Geneeskd. 2021 Oct 7;165:D6173.
8
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.成功使用 casirivimab/imdevimab 抗刺突单克隆抗体增强了一名接受抗 CD20 治疗的难治性 COVID-19 女性的中和抗体。
J Infect Chemother. 2022 Jul;28(7):991-994. doi: 10.1016/j.jiac.2022.03.002. Epub 2022 Mar 23.
9
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.肿瘤治疗性单克隆抗体的药代动力学/药效学关系：第 2 部分，免疫检查点抑制剂抗体。
Eur J Cancer. 2020 Mar;128:119-128. doi: 10.1016/j.ejca.2020.01.003. Epub 2020 Feb 6.
10
Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎BA.1和德尔塔AY.4.2变异株对接受不同授权单克隆抗体治疗患者血清中和作用的影响。
Clin Microbiol Infect. 2022 Jul;28(7):1037-1039. doi: 10.1016/j.cmi.2022.03.005. Epub 2022 Mar 15.
引用本文的文献
1
Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines.延长疫苗半衰期作为提高亚单位疫苗免疫应答持久性的新策略。
PLoS Pathog. 2025 Jan 8;21(1):e1012845. doi: 10.1371/journal.ppat.1012845. eCollection 2025 Jan.
2
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.替沙格韦单抗/西加韦单抗用于肾移植受者暴露前预防的安全性和有效性：一项多中心回顾性队列研究。
J Nephrol. 2024 Jul;37(6):1539-1550. doi: 10.1007/s40620-024-01889-9. Epub 2024 May 23.
3
The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review.环糊精在 COVID-19 治疗中的作用——文献综述。
Int J Mol Sci. 2023 Feb 3;24(3):2974. doi: 10.3390/ijms24032974.
本文引用的文献
1
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.S309 和 AZD7442 单克隆抗体治疗对 SARS-CoV-2 奥密克戎谱系株感染的抵抗力。
Nat Commun. 2022 Jul 2;13(1):3824. doi: 10.1038/s41467-022-31615-7.
2
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.肌肉注射 AZD7442（替沙格韦单抗-西加韦单抗）预防新冠病毒感染。
N Engl J Med. 2022 Jun 9;386(23):2188-2200. doi: 10.1056/NEJMoa2116620. Epub 2022 Apr 20.
3
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
4
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans.SARS-CoV-2 单克隆抗体组合药物 AZD7442 在非人类灵长类动物中具有保护作用，在人体内半衰期延长。
Sci Transl Med. 2022 Mar 9;14(635):eabl8124. doi: 10.1126/scitranslmed.abl8124.
5
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
6
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.SARS-CoV-2 变体中和的双抗体鸡尾酒的遗传和结构基础。
Nat Microbiol. 2021 Oct;6(10):1233-1244. doi: 10.1038/s41564-021-00972-2. Epub 2021 Sep 21.
7
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.巴尼韦单抗/依特司韦单抗在轻中度 COVID-19 中的应用。
N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14.
8
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
9
Potently neutralizing and protective human antibodies against SARS-CoV-2.强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.
10
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
Zotero 插件